A neuroscience mystery has been solved by using artificial intelligence (AI) to identify the electrical signatures of different types of brain neurons for the first time.
The team at Rush University Medical Center have conducted the first US investigation into opioid use and pancreatic cancer - how could this change prescriptions?
While cities only occupy around 3% of the Earth, they are where 50% of the world's population live - but they are not usually included in global climate calculations, meaning that urban environmental problems can slip under the radar.
Jane C Khoury & Shelley R Ehrlich from Division of Biostatistics and Epidemiology, Cincinnati Children’s Hospital Medical Center, highlight the consequences of foetal development in a “sweet” uterus – including the short- and long-term transgenerational outcomes.
Here, we discover that SymlConnect digitises the paper-processes, offering remote monitoring to improve efficiency in care monitoring and reducing the waiting list exacerbated by the COVID-19 pandemic.
Frank F Vincenzi, Professor Emeritus, University of Washington, tells us about the mammalian dive response (MDR), drawing on the case of the woman who developed a fatal heart rhythm while SCUBA diving.
In 2018 the UK proposed stronger 'online harms' regulation, to address harmful content that children can see on social media - by asking tech giants to do better self-regulation or face Government investigation.
While diabetes has been declared as a signifier for infection complications, researchers now say that data suggests it is three times as likely these individuals have severe COVID or are hospitalised.
According to the American Heart Association, women face a stronger heart attack risk than men - they are 20% more likely to develop heart failure, and to die.
Teva and Cephalon faced the €60.5 million antitrust fine, after both companies were found to be actively suppressing the existence of cheaper medicine.
The Oxford and AstraZeneca vaccine trial gave an accidental half-dose to 3,000 people - but this mistake is the reason the vaccine acted as 90% efficient.
Today (20 November) Pfizer and BioNTech are sending their drug for approval to the FDA, meaning that the most vulnerable Americans could get the vaccine in December.
